



Home » Financials

## FINANCIALS

### Revenue Bifurcation

Due to a sustainable growth strategy and robust business model, Intas has achieved a healthy top and bottom line, year on year. The company's successful track record of landmark acquisitions is built entirely on the foundation of robust financial strength.




### FINANCIAL SUMMARY

(US\$ Mn)

Revenue from Operations 1884	Profit after Tax 204
Net Block including CWIP 1281	Profit before Interest, Depreciation & Tax 359

Growth in Revenue From International Operations (US\$ Mn)

CAGR 2012-2019 : 32.2%



Region Wise Revenue Contribution for FY 2018-19 (US\$ Mn)

Region	Revenue Contribution
India	31%
US	18%
EU	42%
Emerging Markets	9%

Revenue Growth (US\$ Mn)

CAGR 2012-2019 : 26.8%



Merger & Acquisitions Track Record



**Corporate Office**  
 Intas Pharmaceuticals Ltd.  
 Corporate House, Near Sola Bridge, S. G.  
 Highway, Thaltej, Ahmedabad - 380054.  
 Gujarat, India.  
 T: +91 79 6157 7000  
 E: generalqueries@intaspharma.com

#### Our Links

- Home
- About Us
- Featured Products
- Financials
- Products
- Media
- R & D
- Careers
- CSR
- Environment
- Investor's information
- Adverse event reporting
- Technical Support

Follow us on



Atossa Therapeutics, Inc. Exhibit 2004  
 Intas Pharms Ltd. v. Atossa Therapeutics, Inc.  
 PGR2025-00043  
 Page 00001